Candel Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Candel Therapeutics, Inc. (Nasdaq: CADL) on June 23, 2025, reporting events occurring on June 20, 2025. The filing addresses the appointment of a new Chief Financial Officer and related compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive personnel changes and compensation.
Material Changes
The primary material change is the appointment of Charles Schoch as Chief Financial Officer, effective June 20, 2025. Mr. Schoch transitions from his role as Interim CFO, which he held since January 2024. He has been with the company since November 2021.
Management Commentary and Compensation Details
In connection with the appointment, the Board approved the following compensatory arrangements for Mr. Schoch:
- Base Salary: Increased to $440,000 annually.
- Annual Bonus: Eligible for a target bonus of 40% of base salary.
- Equity Award: Granted an option to purchase 50,000 shares of common stock at fair market value on the grant date.
- Vesting Schedule: 25% vests on the one-year anniversary of the effective date; the remaining 75% vests in equal installments over the subsequent 36 months, subject to continued employment.
Mr. Schoch is also eligible to participate in standard employee benefit plans. The filing states there are no family relationships between Mr. Schoch and directors or officers, and no undisclosed transactions requiring Item 404(a) disclosure.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 50,000 share option grant.
- Confirm the total annualized compensation package including the target bonus.
- Review the press release (Exhibit 99.1) for additional context on the leadership transition.
- Check subsequent filings for any changes to the company's financial outlook resulting from this leadership appointment.